Fragile X syndrome: from gene discovery to therapy
Open accessThe DOI matches its Crossref record; 73 of the 73 references it cites were found in a registry or an index.
Abstract
A dynamic mutation in the fragile X mental retardation 1 gene, FMR1, was found to cause fragile X syndrome almost 20 years ago. Since, a wealth of information regarding the function of the gene has been gathered. It plays a role in RNA transport and stability and RNA-binding influences the function of a multitude of other genes. In this review, we focus on the recent knowledge of molecular and biochemical pathways shown to be relevant in the fragile X syndrome and how these insights have led to a first series of clinical trials in fragile X patients.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The mGluR theory of fragile X mental retardation
Bear, M. F., Huber, K. M., & Warren, S. T. (2004) · Trends in Neurosciences · doi:10.1016/j.tins.2004.04.009 · Cited by 1,580 · cited 1×
“The mGluR theory In fragile X mice, an increase in postsynaptic group 1 metabotropic glutamate receptor (Gp1 mGluR1/5)dependent LTD was found (114).”
BackgroundAltered synaptic plasticity in a mouse model of fragile X mental retardation
Huber, K. M., Gallagher, S. M., Warren, S. T., & Bear, M. F. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.122205699 · Cited by 1,349 · cited 1×
“Moreover, electrophysiological measurements showed an increase in mGluR-dependent long-term depression (LTD) in the hippocampus of Fmr1 KO mice (80).”
BackgroundFritschy, J., & Mohler, H. (1995) · Journal of Comparative Neurology · doi:10.1002/cne.903590111 · Cited by 1,244
Brown, V., Jin, P., Ceman, S., Darnell, J. C., O'Donnell, W. T., Tenenbaum, S. A., Jin, X., Feng, Y., Wilkinson, K. D., Keene, J. D., et al. (2001) · Cell · doi:10.1016/s0092-8674(01)00568-2 · Cited by 1,109 · cited 2×
“Many mRNAs that bind FMRP are involved in neuronal functions like synapse formation, neurite outgrowth and neuronal development (33, 34).”
BackgroundAbnormal dendritic spines in fragile X knockout mice: Maturation and pruning deficits
Comery, T. A., Harris, J. B., Willems, P. J., Oostra, B. A., Irwin, S. A., Weiler, I. J., & Greenough, W. T. (1997) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.94.10.5401 · Cited by 1,046
Molecular and neuronal substrate for the selective attenuation of anxiety
Löw, K., Crestani, F., Keist, R., Benke, D., Brünig, I., Benson, J. A., Fritschy, J.-M., Rülicke, T., Bluethmann, H., Möhler, H., et al. (2000) · Science · doi:10.1126/science.290.5489.131 · Cited by 946 · cited 1×
“It is known that the sedative effect of benzodiazepines is mediated by alpha 1 containing GABAA receptors (166), while alpha 2 and alpha 3 containing subtypes are responsible for the anxiolytic effects (167, 168).”
BackgroundMcKernan, R. M., Rosahl, T. W., Reynolds, D. S., Sur, C., Wafford, K. A., Atack, J. R., Farrar, S., Myers, J., Cook, G., Ferris, P., et al. (2000) · Nature Neuroscience · doi:10.1038/75761 · Cited by 944
Fragile X-related protein and VIG associate with the RNA interference machinery
Caudy, A. A., Myers, M., Hannon, G. J., & Hammond, S. M. (2002) · Genes & Development · doi:10.1101/gad.1025202 · Cited by 655
The protein product of the fragile X gene, FMR1, has characteristics of an RNA-binding protein.
Siomi, H., Siomi, M. C., Nussbaum, R. L., & Dreyfuss, G. (1993) · Cell · doi:10.1016/0092-8674(93)90420-u · Cited by 641
Dendritic Spine Structural Anomalies in Fragile-X Mental Retardation Syndrome
Irwin, S. A. (2000) · Cerebral Cortex · doi:10.1093/cercor/10.10.1038 · Cited by 626
Advances in the Treatment of Fragile X Syndrome
Hagerman, R. J., Berry-Kravis, E., Kaufmann, W. E., Ono, M. Y., Tartaglia, N., Lachiewicz, A., Kronk, R., Delahunty, C., Hessl, D., Visootsak, J., et al. (2009) · Pediatrics · doi:10.1542/peds.2008-0317 · Cited by 596 · cited 4×
“of ADHD-like symptoms in boys with the fragile X syndrome (159).”
BackgroundInfluentialA Drosophila fragile X protein interacts with components of RNAi and ribosomal proteins
Ishizuka, A., Siomi, M. C., & Siomi, H. (2002) · Genes & Development · doi:10.1101/gad.1022002 · Cited by 581 · cited 1×
“Mammalian FMRP as well as the drosophila ortholog, dFmrp, associates with several components of the miRNA pathway including Dicer, Ago1/2 (Argonaute) and miRNAs (56-58).”
BackgroundEvidence that fragile X mental retardation protein is a negative regulator of translation
Laggerbauer, B. (2001) · Human Molecular Genetics · doi:10.1093/hmg/10.4.329 · Cited by 571
Abnormal Development of Dendritic Spines in FMR1 Knock-Out Mice
Nimchinsky, E. A., Oberlander, A. M., & Svoboda, K. (2001) · The Journal of Neuroscience · doi:10.1523/jneurosci.21-14-05139.2001 · Cited by 560 · cited 1×
“No gross pathological abnormalities in brain were observed, but increased spine density and excess of long and thin immature spines, has also been described (74-76).”
BackgroundBenzodiazepines: use, abuse, and consequences.
Woods, J. H., Katz, J. L., & Winger, G. (1992) · Pharmacological Reviews · doi:10.1016/s0031-6997(25)00468-5 · Cited by 560 · cited 1×
“Benzodiazepines have anticonvulsant and anxiolytic effects, but display side effects like sedation, ataxia, tolerance and dependence (164).”
BackgroundDysregulation of mTOR signaling in fragile X syndrome
Sharma, A., Hoeffer, C. A., Takayasu, Y., Miyawaki, T., McBride, S. M., Klann, E., & Zukin, R. S. (2010) · The Journal of Neuroscience · doi:10.1523/jneurosci.3696-09.2010 · Cited by 557
Feng, Y., Gutekunst, C.-A., Eberhart, D. E., Yi, H., Warren, S. T., & Hersch, S. M. (1997) · The Journal of Neuroscience · doi:10.1523/jneurosci.17-05-01539.1997 · Cited by 532
Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGluR5 antagonist MPEP
Yan, Q. J., Rammal, M., Tranfaglia, M., & Bauchwitz, R. P. (2005) · Neuropharmacology · doi:10.1016/j.neuropharm.2005.06.004 · Cited by 521 · cited 1×
“In addition, after MPEP treatment of primary hippocampal neurons in vitro, less immature spines were measured (82, 176).”
BackgroundThe Promise of Minocycline in Neurology
Yong, V. W., Wells, J., Giuliani, F., Casha, S., Power, C., & Metz, L. M. (2004) · The Lancet Neurology · doi:10.1016/s1474-4422(04)00937-8 · Cited by 518
RNA cargoes associating with FMRP reveal deficits in cellular functioning in Fmr1 null mice
Miyashiro, K. Y., Beckel-Mitchener, A., Purk, T. P., Becker, K. G., Barret, T., Liu, L., Carbonetto, S., Weiler, I. J., Greenough, W. T., & Eberwine, J. (2003) · Neuron · doi:10.1016/s0896-6273(03)00034-5 · Cited by 495
The fragile X mental retardation protein binds specifically to its mRNA via a purine quartet motif
Schaeffer, C., Bardoni, B., Mandel, J., Ehresmann, B., Ehresmann, C., & Moine, H. (2001) · The EMBO Journal · doi:10.1093/emboj/20.17.4803 · Cited by 471 · cited 1×
“FMRP has a preference for two classes of mRNAs that contain either a G-quartet structure or a U-rich sequence (34-37).”
BackgroundIncidence of Fragile X Syndrome by Newborn Screening for Methylated FMR1 DNA
Coffee, B., Keith, K., Albizua, I., Malone, T., Mowrey, J., Sherman, S. L., & Warren, S. T. (2009) · The American Journal of Human Genetics · doi:10.1016/j.ajhg.2009.09.007 · Cited by 436 · cited 1×
“Fragile X syndrome is the most common form of inherited mental retardation, with a prevalence of 1/2500 – 1/6000 (1, 2).”
BackgroundA pilot open label, single dose trial of fenobam in adults with fragile X syndrome
Berry-Kravis, E., Hessl, D., Coffey, S., Hervey, C., Schneider, A., Yuhas, J., Hutchison, J., Snape, M., Tranfaglia, M., Nguyen, D. V., et al. (2009) · Journal of Medical Genetics · doi:10.1136/jmg.2008.063701 · Cited by 411 · cited 1×
“In 2009, a first clinical study using a single oral dose of fenobam was conducted to provide an initial evaluation of safety and pharmacokinetics in adults with fragile X syndrome (178).”
MethodEberhart, D. (1996) · Human Molecular Genetics · doi:10.1093/hmg/5.8.1083 · Cited by 390
Matrix metalloproteinases in brain development and remodeling: Synaptic functions and targets
Ethell, I. M., & Ethell, D. W. (2007) · Journal of Neuroscience Research · doi:10.1002/jnr.21273 · Cited by 378 · cited 1×
“Some MMPs, such as MMP-9, can influence the spine morphology by cleaving extracellular matrix (ECM) or membrane proteins that are implicated in synapse formation and dendritic spine maturation (195).”
BackgroundRho proteins, mental retardation and the cellular basis of cognition
Ramakers, G. J. A. (2002) · Trends in Neurosciences · doi:10.1016/s0166-2236(00)02118-4 · Cited by 374
Schenck, A., Bardoni, B., Moro, A., Bagni, C., & Mandel, J.-L. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.151231598 · Cited by 356
Fragile X mice develop sensory hyperreactivity to auditory stimuli
Chen, L., & Toth, M. (2001) · Neuroscience · doi:10.1016/s0306-4522(01)00036-7 · Cited by 345
Phosphorylation influences the translation state of FMRP-associated polyribosomes
Ceman, S., O'Donnell, W. T., Reed, M., Patton, S., Pohl, J., & Warren, S. T. (2003) · Human Molecular Genetics · doi:10.1093/hmg/ddg350 · Cited by 327
Decreased expression of the GABAA receptor in fragile X syndrome
D'Hulst, C., De Geest, N., Reeve, S. P., Van Dam, D., De Deyn, P. P., Hassan, B. A., & Kooy, R. F. (2006) · Brain Research · doi:10.1016/j.brainres.2006.08.115 · Cited by 318
Schenck, A., Bardoni, B., Langmann, C., Harden, N., Mandel, J.-L., & Giangrande, A. (2003) · Neuron · doi:10.1016/s0896-6273(03)00354-4 · Cited by 316
Rescue of behavioral phenotype and neuronal protrusion morphology in Fmr1 KO mice
de Vrij, F. M. S., Levenga, J., van der Linde, H. C., Koekkoek, S. K., De Zeeuw, C. I., Nelson, D. L., Oostra, B. A., & Willemsen, R. (2008) · Neurobiology of Disease · doi:10.1016/j.nbd.2008.04.002 · Cited by 313 · cited 11×
“MPEP was also able to rescue the open field phenotype and the prepulse inhibition of acoustic startle (PPI) phenotype observed in fragile X mice.”
BackgroundInfluentialPorter, R. H. P., Jaeschke, G., Spooren, W., Ballard, T. M., Büttelmann, B., Kolczewski, S., Peters, J.-U., Prinssen, E., Wichmann, J., Vieira, E., et al. (2005) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089839 · Cited by 308
Paradee, W., Melikian, H. E., Rasmussen, D. L., Kenneson, A., Conn, P. J., & Warren, S. T. (1999) · Neuroscience · doi:10.1016/s0306-4522(99)00285-7 · Cited by 305
Deficits in trace fear memory and long-term potentiation in a mouse model for fragile X syndrome
Zhao, M.-G., Toyoda, H., Ko, S. W., Ding, H.-K., Wu, L.-J., & Zhuo, M. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.1520-05.2005 · Cited by 296 · cited 1×
“A decreased expression of the mGluR1 receptor was found in the cerebral cortex and a reduced long-term potentiation (LTP) was found in the cortex of the fragile X mouse (77-79).”
BackgroundAudiogenic Seizures Susceptibility in Transgenic Mice with Fragile X Syndrome
Musumeci, S. A., Bosco, P., Calabrese, G., Bakker, C., De Sarro, G. B., Elia, M., Ferri, R., & Oostra, B. A. (2000) · Epilepsia · doi:10.1111/j.1528-1157.2000.tb01499.x · Cited by 289
(Over)correction of FMR1 deficiency with YAC transgenics: behavioral and physical features
Peier, A. M. (2000) · Human Molecular Genetics · doi:10.1093/hmg/9.8.1145 · Cited by 285
Inhibition of p21-activated kinase rescues symptoms of fragile X syndrome in mice
Hayashi, M. L., Rao, B. S. S., Seo, J.-S., Choi, H.-S., Dolan, B. M., Choi, S.-Y., Chattarji, S., & Tonegawa, S. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0705003104 · Cited by 281 · cited 7×
“Underexpression of LARG could lead to less activation of RhoA and, as a consequence, cause changes in neuron outgrowth and formation of immature spines. p21-activated kinase (PAK) is the final known link between FMRP and Rho GTPases (132).”
BackgroundInfluentialIrwin, S. A., Idupulapati, M., Gilbert, M. E., Harris, J. B., Chakravarti, A. B., Rogers, E. J., Crisostomo, R. A., Larsen, B. P., Mehta, A., Alcantara, C. J., et al. (2002) · American Journal of Medical Genetics · doi:10.1002/ajmg.10500 · Cited by 270
Analysis of the set of GABAA receptor genes in the human genome
Simon, J., Wakimoto, H., Fujita, N., Lalande, M., & Barnard, E. A. (2004) · Journal of Biological Chemistry · doi:10.1074/jbc.m401354200 · Cited by 253 · cited 1×
“Like other types of ionotropic receptors, GABAA receptors are pentamers assembled from a combination of 19 possible known subunits; alpha 1-6, beta 1-3, gamma 13 delta, epsilon, pi, theta and rho 1-3 (160).”
BackgroundThe fragile X mental retardation protein is associated with ribosomes
Khandjian, E. W., Corbin, F., Woerly, S., & Rousseau, F. (1996) · Nature Genetics · doi:10.1038/ng0196-91 · Cited by 251 · cited 1×
“FMRP is associated with the 60S subunit of the ribosomes in an RNA-dependent manner (31, 32).”
BackgroundSelby, L., Zhang, C., & Sun, Q.-Q. (2007) · Neuroscience Letters · doi:10.1016/j.neulet.2006.11.062 · Cited by 245
p140Sra-1 (specifically Rac1-associated protein) is a novel specific target for Rac1 small GTPase
Kobayashi, K., Kuroda, S., Fukata, M., Nakamura, T., Nagase, T., Nomura, N., Matsuura, Y., Yoshida-Kubomura, N., Iwamatsu, A., & Kaibuchi, K. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.1.291 · Cited by 244 · cited 1×
“CYFIP1/2 interacts with Rac1 which plays a role in the dynamic reorganisation of the actin cytoskeleton (125).”
BackgroundNarayanan, U., Nalavadi, V., Nakamoto, M., Pallas, D. C., Ceman, S., Bassell, G. J., & Warren, S. T. (2007) · The Journal of Neuroscience · doi:10.1523/jneurosci.2969-07.2007 · Cited by 228 · cited 5×
“U. Narayanan, V. Nalavadi, M. Nakamoto, D. C. Pallas, S. Ceman, G. J. Bassell & S. T. Warren: FMRP phosphorylation reveals an immediate-early signaling pathway triggered by group I mGluR and mediated by PP2A.”
BackgroundInfluentialBehavioral and neuroanatomical characterization of the Fmr1 knockout mouse
Mineur, Y. S., Sluyter, F., de Wit, S., Oostra, B. A., & Crusio, W. E. (2002) · Hippocampus · doi:10.1002/hipo.10005 · Cited by 216 · cited 2×
“In contrast to humans, fragile X mice show increased exploratory behaviour (62, 67, 71) and some tests show a reduced anxiety-related response (65, 67, 68, 7072).”
BackgroundNarayanan, U., Nalavadi, V., Nakamoto, M., Thomas, G., Ceman, S., Bassell, G. J., & Warren, S. T. (2008) · Journal of Biological Chemistry · doi:10.1074/jbc.c800055200 · Cited by 216 · cited 1×
“The phosphatase responsible for the dephosphorylation of FMRP is PP2A (116), whereas the phosphorylation of FMRP occurs through protein S6 kinase 1 (S6K1), which is ERK and mammalian target of rapamycin (mTOR) signalling mediated (117, 118).”
BackgroundOpen-Label Treatment Trial of Lithium to Target the Underlying Defect in Fragile X Syndrome
Berry-Kravis, E., Sumis, A., Hervey, C., Nelson, M., Porges, S. W., Weng, N., Weiler, I. J., & Greenough, W. T. (2008) · Journal of Developmental & Behavioral Pediatrics · doi:10.1097/dbp.0b013e31817dc447 · Cited by 215 · cited 1×
“An open-label trial in male fragile X patients resulted in a significant improvement in behavioural functioning, adaptive behaviour and verbal memory (184).”
BackgroundA phenotypic and molecular characterization of the fmr1‐tm1Cgr Fragile X mouse
Yan, Q. J., Asafo‐Adjei, P. K., Arnold, H. M., Brown, R. E., & Bauchwitz, R. P. (2004) · Genes, Brain and Behavior · doi:10.1111/j.1601-183x.2004.00087.x · Cited by 213
Weiler, I. J., Spangler, C. C., Klintsova, A. Y., Grossman, A. W., Kim, S. H., Bertaina-Anglade, V., Khaliq, H., de Vries, F. E., Lambers, F. A. E., Hatia, F., et al. (2004) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0407533101 · Cited by 210 · cited 1×
“The PKC pathway is implicated in dendritic mRNA translation by regulating transcription factors and translation initiation (183).”
BackgroundMildly impaired water maze performance in maleFmr1 knockout mice
D'Hooge, R., Nagels, G., Franck, F., Bakker, C. E., Reyniers, E., Storm, K., Kooy, R. F., Oostra, B. A., Willems, P. J., & De Deyn, P. P. (1997) · Neuroscience · doi:10.1016/s0306-4522(96)00224-2 · Cited by 208 · cited 1×
“and memory deficits (62-66), slightly increased locomotor activity (62, 67, 68) and altered sensorimotor integration (67, 69, 70).”
BackgroundHessl, D., Dyer-Friedman, J., Glaser, B., Wisbeck, J., Barajas, R. G., Taylor, A., & Reiss, A. L. (2001) · Pediatrics · doi:10.1542/peds.108.5.e88 · Cited by 201 · cited 1×
“In several studies with fragile X children, it was already shown that a higherquality in home and school environment is associated with less autistic behaviour, better adaptive behaviour and higher IQ scores (154-156).”
BackgroundGrant, P., Lougee, L., Hirschtritt, M., & Swedo, S. E. (2007) · Journal of Child and Adolescent Psychopharmacology · doi:10.1089/cap.2007.0021 · Cited by 197 · cited 3×
“Given the overlap between repetitive behaviour in the fragile X syndrome and OCD symptoms, a phase IV clinical trial is planned.”
BackgroundInfluentialCharacterization of the full fragile X syndrome mutation in fetal gametes
Malter, H. E., Iber, J. C., Willemsen, R., Graaff, E. D., Tarleton, J. C., Leisti, J., Warren, S. T., & Oostra, B. A. (1997) · Nature Genetics · doi:10.1038/ng0297-165 · Cited by 197
Atack, J. R., Wafford, K. A., Tye, S. J., Cook, S. M., Sohal, B., Pike, A., Sur, C., Melillo, D., Bristow, L., Bromidge, F., et al. (2006) · The Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.105.089920 · Cited by 188
Ceman, S., Brown, V., & Warren, S. T. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.12.7925 · Cited by 181
Abnormal Striatal GABA Transmission in the Mouse Model for the Fragile X Syndrome
Centonze, D., Rossi, S., Mercaldo, V., Napoli, I., Ciotti, M. T., De Chiara, V., Musella, A., Prosperetti, C., Calabresi, P., Bernardi, G., et al. (2008) · Biological Psychiatry · doi:10.1016/j.biopsych.2007.09.008 · Cited by 171 · cited 1×
“Electrophysiological studies demonstrated that absence of FMRP is associated with apparently normal striatal glutamate-mediated transmission, but abnormal GABA transmission (109).”
BackgroundThe neuroanatomy and neuroendocrinology of fragile X syndrome
Hessl, D., Rivera, S. M., & Reiss, A. L. (2004) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.20004 · Cited by 165
FMRP interferes with the Rac1 pathway and controls actin cytoskeleton dynamics in murine fibroblasts
Castets, M., Schaeffer, C., Bechara, E., Schenck, A., Khandjian, E. W., Luche, S., Moine, H., Rabilloud, T., Mandel, J.-L., & Bardoni, B. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi077 · Cited by 162 · cited 1×
“Moreover, Rac1 activation leads to relocalization of four FMRP main interactors (CYFIP1, FXR1P, NUFIP and 82FIP) to actin-containing domains called actin rings (128).”
BackgroundChen, L., Yun, S.-W., Seto, J., Liu, W., & Toth, M. (2003) · Neuroscience · doi:10.1016/s0306-4522(03)00406-8 · Cited by 160 · cited 1×
“FMRP has a preference for two classes of mRNAs that contain either a G-quartet structure or a U-rich sequence (34-37).”
BackgroundA controlled trial of stimulant medication in children with the fragile X syndrome
Hagerman, R. J., Murphy, M. A., & Wittenberger, M. D. (1988) · American Journal of Medical Genetics · doi:10.1002/ajmg.1320300138 · Cited by 158 · cited 1×
“Two used stimulants are methylphenidate (Ritalin) and dextroamphetamine (Adderall) (158).”
BackgroundPsychopharmacology in fragile X syndrome—Present and future
Berry‐Kravis, E., & Potanos, K. (2004) · Mental Retardation and Developmental Disabilities Research Reviews · doi:10.1002/mrdd.20007 · Cited by 151
Min, W. W., Yuskaitis, C. J., Yan, Q., Sikorski, C., Chen, S., Jope, R. S., & Bauchwitz, R. P. (2009) · Neuropharmacology · doi:10.1016/j.neuropharm.2008.09.017 · Cited by 146
A mouse model of the human Fragile X syndrome I304N mutation
Zang, J. B., Nosyreva, E. D., Spencer, C. M., Volk, L. J., Musunuru, K., Zhong, R., Stone, E. F., Yuva-Paylor, L. A., Huber, K. M., Paylor, R., et al. (2009) · PLoS Genetics · doi:10.1371/journal.pgen.1000758 · Cited by 138
Bardoni, B., Schenck, A., & Louis Mandel, J. (1999) · Human Molecular Genetics · doi:10.1093/hmg/8.13.2557 · Cited by 136
Larson, J., Jessen, R. E., Kim, D., Fine, A.-K. S., & du Hoffmann, J. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2638-05.2005 · Cited by 135 · cited 1×
“A decreased expression of the mGluR1 receptor was found in the cerebral cortex and a reduced long-term potentiation (LTP) was found in the cortex of the fragile X mouse (77-79).”
BackgroundPacey, L. K. K., Heximer, S. P., & Hampson, D. R. (2009) · Molecular Pharmacology · doi:10.1124/mol.109.056127 · Cited by 133 · cited 1×
“Recently, it was shown that treatment with a GABAB receptor agonist, baclofen, is able to inhibit the audiogenic seizures in Fmr1 knockout mice (186).”
BackgroundUtari, A., Chonchaiya, W., Rivera, S. M., Schneider, A., Hagerman, R. J., Faradz, S. M. H., Ethell, I. M., & Nguyen, D. V. (2010) · American Journal on Intellectual and Developmental Disabilities · doi:10.1352/1944-7558-115.5.433 · Cited by 105 · cited 1×
“A first clinical trial for the fragile X syndrome showed especially improvements in general cognition, language, attention, social communication and anxiety (197).”
BackgroundPilpel, Y., Kolleker, A., Berberich, S., Ginger, M., Frick, A., Mientjes, E., Oostra, B. A., & Seeburg, P. H. (2009) · The Journal of Physiology · doi:10.1113/jphysiol.2008.160929 · Cited by 102
Genetic and Environmental Influences on the Cognitive Outcomes of Children With Fragile X Syndrome
DYER-FRIEDMAN, J., GLASER, B., HESSL, D., JOHNSTON, C., HUFFMAN, L. C., TAYLOR, A., WISBECK, J., & REISS, A. L. (2002) · Journal of the American Academy of Child & Adolescent Psychiatry · doi:10.1097/00004583-200203000-00002 · Cited by 100 · cited 1×
“In several studies with fragile X children, it was already shown that a higherquality in home and school environment is associated with less autistic behaviour, better adaptive behaviour and higher IQ scores (154-156).”
BackgroundDaily injections alter spine density in rat medial prefrontal cortex
Seib, L. M., & Wellman, C. L. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(02)01287-9 · Cited by 100
Aberrant early-phase ERK inactivation impedes neuronal function in fragile X syndrome
Kim, S. H., Markham, J. A., Weiler, I. J., & Greenough, W. T. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0800257105 · Cited by 97
Phosphorylation of FMRP inhibits association with Dicer
Cheever, A., & Ceman, S. (2009) · RNA · doi:10.1261/rna.1500809 · Cited by 81
Musumeci, S. A., Calabrese, G., Bonaccorso, C. M., D'Antoni, S., Brouwer, J. R., Bakker, C. E., Elia, M., Ferri, R., Nelson, D. L., Oostra, B. A., et al. (2007) · Experimental Neurology · doi:10.1016/j.expneurol.2006.08.007 · Cited by 70
Cited by
CGG repeat in the FMR1 gene: size matters
Willemsen, R., Levenga, J., & Oostra, B. (2011) · Clinical Genetics · doi:10.1111/j.1399-0004.2011.01723.x · Cited by 184
Veenstra-VanderWeele, J., & Blakely, R. D. (2012) · Neuropsychopharmacology · doi:10.1038/npp.2011.185 · Cited by 128
“As reviewed below and elsewhere (Bhogal and Jongens, 2010; Heulens and Kooy, 2011), significant progress has been made in understanding the molecular changes that connect loss of FMR1 expression to the observed neurological, cognitive, and behavioral abnormalities in the mouse model.”
BackgroundPyronneau, A., He, Q., Hwang, J.-Y., Porch, M., Contractor, A., & Zukin, R. S. (2017) · Science Signaling · doi:10.1126/scisignal.aan0852 · Cited by 122
“FXS causes a complex and debilitating neurological phenotype including impaired cognition, social/language deficits, increased susceptibility to seizures, attentional deficits, hyperactivity, sleep disturbances, motor incoordination, and hypersensitivity to sensory stimuli (2, 7, 8).”
BackgroundIntervention in the Context of Development: Pathways Toward New Treatments
Veenstra-VanderWeele, J., & Warren, Z. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2014.232 · Cited by 34
“Much progress has been made in understanding the molecular changes that connect loss of FMR1 expression to observed cognitive and behavioral symptoms (Heulens and Kooy, 2011).”
Background
Metadata
- Authors
- Heulens, I.
- Venue
- Frontiers in Bioscience
- Publisher
- IMR Press
- Published
- 2011
- Volume
- 16
- Issue
- 1
- Pages
- 1211
- ISSN
- 1093-4715 (ISSN-L)
- 1093-9946
- DOI
- 10.2741/3785
- OpenAlex
- W2081538214
- Cited by
- 31
- References
- 73
- FWCI
- 3.19
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.